Drug Trial Radar · NCT03078907
Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.
Last checked: Nov 20, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
108
Actual
Start
Nov 8, 2017
Primary completion
Feb 10, 2020
Study completion Feb 10, 2020
Sponsor
- Lead sponsor
- ActelionJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Mar 14, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the effect of selexipag on the physical activity of patients with pulmonary arterial hypertension (PAH) in their daily life, by using a wearable wrist device (actigraph). The actigraph will collect data on daily life physical activity in the patient's real environment. In addition, the PAH symptoms and their impacts will be assessed by using an electronic patient reported outcome measure in the patient's real environment. Patients will be assigned randomly to either selexipag or placebo.
Conditions
- Pulmonary Arterial Hypertension
Interventions
SelexipagDrug
Film-coated tablets for oral use; one tablet (200 mcg) to eight tablets (1600 mcg) are administered depending on the individual tolerability.
PlaceboDrug
Matching film coated tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 24 in Actigraphy Assessed Daily Life Physical Activity (DLPA) for Variables Expressed in MinutesTime frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
- Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Percentage (%)Time frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
- Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Counts Per Minute (Counts/Minute)Time frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
- Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in CountsTime frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
- Change From Baseline to Week 24 in Actigraphy DLPA for Variable Expressed in Step CountsTime frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
- Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Step Counts/MinuteTime frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
- Change From Baseline to Week 24 in Total Sleep Time (TST)Time frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
- Change From Baseline to Week 24 in Wake After Sleep Onset (WASO)Time frame: Baseline and Week 24 (data collection was done during 14-Days each for Baseline and for Week 24)
- Change From Baseline to Week 24 in Number of AwakeningsTime frame: Baseline and Week 24 (data collection was done during 14-Days each for Baseline and for Week 24)
- Change From Baseline to Week 24 in Sleep Efficiency (SE)Time frame: Baseline and Week 24 (data collection was done during 14-Days each for Baseline and for Week 24)
Locations
39 sites in 10 countries. Site status is shown where the registry gives one.
LA Biomedical Research Institute
Torrance, California
Northside Hospital
Atlanta, Georgia
Kentuckiana Pulmonary Research Center
Louisville, Kentucky
Tufts Medical Center, Pulmonary/Critical Care & Sleep
Boston, Massachusetts
University of Nebraska Medical Center, Pulmonary, Critical Care & Sleep Medicine Division
Omaha, Nebraska
NYU Winthrop Hospital
Mineola, New York
UNC Pulmonary Speciality Clinic
Chapel Hill, North Carolina
Duke University School of Medicine, Duke Pulmonary Vascular Disease center
Durham, North Carolina
University of Cincinnati, Heart, Lung and Vascular Institute
Cincinnati, Ohio
CCF- Akron General Medical Hospital
Cleveland, Ohio
Integris Baptist Medical Center
Oklahoma City, Oklahoma
University of Pennsylvania, Pulmonary Vascular Disease Program
Philadelphia, Pennsylvania
Vanderbilt University Medical Center, Care Medicine
Nashville, Tennessee
Methodist Clinical Trials
San Antonio, Texas
University of Texas Health Science Center (San Antonio)
San Antonio, Texas
Medizinische Universität Innsbruck (MUI), Abt. für Pneumologie, Haus 2
Innsbruck, Austria
Krankenhaus der Elisabethinen, Servicestelle Klinische Studien
Linz, Austria
Hôpital Bicêtre, ervice de Pneumologie et Réanimation respiratoire
Le Kremlin-Bicêtre, France
CHRU de Lille - Hôpital Albert Calmette, Service de cardiologie
Lille, France
Hospital Larrey CHU de Toulouse
Toulouse, France
Herzzentrum der Universität zu Köln, Klinik III für Innere Medizin
Cologne, Germany
Universitätsklinikum Giessen
Giessen, Germany
Universitätsklinikum Leipzig AöR, Abteilung Pneumologie
Leipzig, Germany
Katholisches Klinikum Lünen/Werne GmbH, Haus E
Lünen, Germany
Mater Misericordiae University Hospital
Dublin, Ireland
Oslo University Hospital, dept of cardiology
Oslo, Norway
Centro Hospitalar e Universitário de Coimbra, Serviço de Cardiologia
Coimbra, Portugal
Hospital Geral de Santo António-DEFI
Porto, Portugal
Sahlgrenska University Hospital, Gothenburg
Gothenburg, Sweden
Skåne University Hospital, VO Hjärt och Lungmedicin
Lund, Sweden
Kantonsspital St. Gallen, Klinik für Pneumologie und Schlafmedizin
Sankt Gallen, Switzerland
Universitaetsspital Zurich, Klinik für Pneumologie C HOER 11
Zurich, Switzerland
Papworth Hospital, Pulmonary Vascular Disease Unit
Cambridge, United Kingdom
Golden Jubilee National Hospital, Scottish Pulmonary Vascular Unit
Clydebank, United Kingdom
The Royal Free Hospital, Cardiology Department
London, United Kingdom
Royal Brompton Hospital, Hypertension
London, United Kingdom
Hammersmith Hospital
London, United Kingdom
Freeman Hospital, Cardiothoracic Department
Newcastle upon Tyne, United Kingdom
Royal Hallamshire Hospital, Pulmonary Vascular Medicine
Sheffield, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.